Navigating the Future of Healthcare: What is the Approval Process for Medical AI?

Rasit Dinc

Rasit Dinc Digital Health & AI Research

Published: December 30, 2022 | Medical Imaging AI

DOI: 10.5281/zenodo.17997664

Abstract

The integration of Artificial Intelligence AI and Machine Learning ML into medical devices and clinical decision support systems is transforming healthcare, ...

The integration of Artificial Intelligence (AI) and Machine Learning (ML) into medical devices and clinical decision support systems is transforming healthcare, promising enhanced efficiency and patient outcomes. This rapid innovation raises a critical question: **What is the approval process for medical AI?**

The regulatory landscape is complex and evolving, focused on ensuring patient safety, efficacy, and data integrity. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are the two most influential bodies in this space.

The FDA’s Approach: Adapting Traditional Pathways for Software as a Medical Device (SaMD)

In the United States, the FDA regulates AI/ML-enabled medical devices under its Center for Devices and Radiological Health (CDRH). Rather than creating an entirely new regulatory category, the FDA has adapted its existing frameworks to accommodate the unique characteristics of software.

Most medical AI applications fall under the category of **Software as a Medical Device (SaMD)**. The specific approval pathway depends on the device's risk level and novelty:

1. **Premarket Clearance (510(k)):** The most common route for lower-to-moderate risk devices substantially equivalent to a legally marketed predicate. Many diagnostic AI tools follow this pathway. 2. **De Novo Classification:** Used for novel, low-to-moderate risk devices with no existing predicate, establishing a new regulatory classification for groundbreaking AI. 3. **Premarket Approval (PMA):** Reserved for high-risk devices that support or sustain human life, requiring the most rigorous scientific evidence.

The Challenge of Adaptive Algorithms: The Total Product Lifecycle

(TPL)

A key regulatory challenge is the nature of continuously learning algorithms. Traditional medical devices are static, but many AI/ML models are designed to evolve and improve based on real-world data. To address this, the FDA has proposed a **Total Product Lifecycle (TPL)** approach. This framework allows for pre-specified changes to the AI model (the "predetermined change control plan") to be implemented without requiring a new submission for every minor update, provided the changes remain within the bounds of the original approval. This shift acknowledges the dynamic nature of AI and aims to foster innovation while maintaining oversight.

The European Perspective: EMA and the AI Act

Across the Atlantic, the European Medicines Agency (EMA) is working in concert with the broader European Union regulatory framework. While the EMA primarily focuses on medicines, its guidelines on AI are crucial for the pharmaceutical and medical device sectors.

The EU's landmark **Artificial Intelligence Act (AI Act)** classifies AI systems based on potential harm, with medical devices generally falling into the **"high-risk"** category. This mandates stringent requirements for data governance, technical documentation, transparency, human oversight, and robustness, aiming to create a harmonized, future-proof legal framework.

Key Considerations for Regulatory Success

For developers and clinicians, navigating this landscape requires a focus on several core principles:

Data Quality and Bias: *The performance of medical AI is intrinsically linked to the quality and representativeness of the training data. Regulators demand rigorous documentation demonstrating that the data is clean, diverse, and free from biases that could lead to health inequities.* **Transparency and Explainability (XAI):** While AI models can be "black boxes," regulators increasingly require a degree of explainability (XAI) to understand *why* a system made a particular decision, especially in high-risk clinical settings. ***Real-World Performance Monitoring:*** *Post-market surveillance is critical. Devices must be monitored in real-world settings to ensure their performance remains consistent and to track the impact of any algorithm updates.*

The journey from an innovative AI concept to a clinically approved tool is arduous, demanding a deep understanding of both technology and regulatory science. For more in-depth analysis on the intersection of digital health, AI, and regulatory strategy, the resources at ***www.rasitdinc.com*** *provide expert commentary and professional insight.*

Conclusion

The approval process for medical AI is a dynamic convergence of established medical device regulation and forward-thinking policy. By adapting pathways like 510(k) and De Novo, and by introducing concepts like the TPL, regulatory

bodies are striving to keep pace with innovation. As AI continues to mature, the focus will remain on establishing robust, transparent, and globally harmonized standards to ensure that these powerful tools are safe, effective, and ultimately benefit all patients.

References* U.S. Food and Drug Administration (FDA). *Artificial Intelligence and Machine Learning (AI/ML) Software as a Medical Device (SaMD) Action Plan*. *European Medicines Agency (EMA).* Artificial intelligence in the regulation of medicines*.* Pantanowitz, L. (2024). Regulatory Aspects of Artificial Intelligence and Machine Learning in Pathology. *Archives of Pathology & Laboratory Medicine*, 148(1), 10-18. *Singh, R., et al. (2025). How AI is used in FDA-authorized medical devices.* npj Digital Medicine*, 8(1), 1-10.
